Market Research Reports - IMARC Group

IMARC Group is a leading adviser of market research worldwide and providing industry market forecasts for biotechnology, advanced materials, pharmaceuticals, food/beverage, travel, tourism, nanotechnology etc.

Global Dry Eye Syndrome Market Projected to Reach US$ 5.1 Billion by 2024

Healthcare

According to the latest report by IMARC Group titled, " Dry Eye Syndrome Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024 ", the market reaches a value of US $ 3.5 Billion in 2018. Looking forward, The market is expected to reach a value of US $ 5.1 Billion by 2024, exhibiting at CAGR of around 6.5% during 2019-2024.

Request for a sample copy of this research report:  https://www.imarcgroup.com/dry-eye-syndrome-market/requestsample

Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is an ailment in which the eyes are not able to produce enough tears or when the tears evaporate too quickly. Although anyone can experience the disease, it is more common in older patients and women. Its symptoms include irritation, redness, discharge, and easily fatigued eyes. Apart from this, watery eyes can also be a symptom as the dry surface of the eyes over-stimulates the production of watery component of tears to reduce the dryness. Several factors can cause dry eye syndrome such as excessive computer use, allergies, aging, menopause and smoking.

f:id:imarcgroup:20190510143214j:plain

The global dry eye syndrome treatment market is driven by the growing geriatric population, the increasing prevalence of the disease and rise in the awareness about its diagnosis and treatment. Moreover, the modern lifestyle which induces eye strain due to the heightened usage of tablets, mobile phones, and computers is further increasing eye-related problems. The other common risk factors associated with this syndrome include environmental conditions and autoimmune disorders with systemic medications. Over the last few years, there has been a rise in the availability of treatment options such as eyedrops, punctual bags and artificial tears, which is expected to add to the market growth. Moreover, focus on the development of novel technologies and the contribution of non-governmental organizations towards the diagnosis of the disease are other factors driving the growth of the market.

 

Market Segmentation:

Breakup by Disease Type 

•    Evaporative Dry Eye Syndrome 
•    Aqueous Dry Eye Syndrome
•    Breakup by Drug Type
•    Lubricant Eye Drops 
•    Anti-inflammatory Drugs 
•    Autologous Serum Eye Drops 

Breakup by Product 

•    Liquid Drops 
•    Gel 
•    Liquid Wipes 
•    Eye Ointment 
•    Others

Breakup by Distribution Channel

•    Retail Pharmacies 
•    Hospital Pharmacies 
•    Online Pharmacies 

Breakup by Region

•    North America
•    Europe
•    Asia Pacific
•    Middle East and Africa
•    Latin America

Competitive Landscape

The report has also examined the competitive landscape of global dry eye syndrome market. Some of the major players in the market are Novartis AG, Allergan plc., Otsuka Holdings Co., Ltd., Santen Pharmaceutical Co., Ltd., Nicox S.A., Auven Therapeutics, Akorn, Inc., Bausch + Lomb, Alimera Science and GlaxoSmithKline plc.

Key highlights of the report:
•    Market Performance
•    Market Outlook
•    Porter’s Five Forces Analysis
•    Market Drivers and Success Factors
•    SWOT Analysis
•    Value Chain
•    Competitive Structure 
•    Profiles of Key Players

Explore full report with table of contents:​​​​​​​ https://www.imarcgroup.com/dry-eye-syndrome-market